GSK vs Gilead: Heavy­weight HIV fight will come down to a big show­down in Am­s­ter­dam next month

One of the most in­tense ri­val­ries in bio­phar­ma R&D to­day cen­ters on the show­down be­tween Glax­o­SmithK­line and Gilead in HIV.

Gilead has dom­i­nat­ed the sec­tor for years, keep­ing a steady hand on the mar­ket and de­vel­op­ing new and bet­ter ther­a­pies, like the block­buster-to-be triple drug Bik­tarvy. But Glax­o­SmithK­line has en­joyed some big ad­vances of its own at its ma­jor­i­ty-owned Vi­iV, and now an­a­lysts ex­pect the in­tense ri­val­ry to come down to the up­com­ing In­ter­na­tion­al AIDS Con­fer­ence in Am­s­ter­dam on Ju­ly 24.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.